PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
23333935-6	2013	In situ Ad.Flagrp170 therapy provokes systemic activation of CTLs that recognize several antigens naturally expressing in melanoma (e.g., gp100/PMEL and TRP2/DCT).	flagrp170	11-20	premelanosome protein	Mus musculus	138-143
23333935-6	2013	In situ Ad.Flagrp170 therapy provokes systemic activation of CTLs that recognize several antigens naturally expressing in melanoma (e.g., gp100/PMEL and TRP2/DCT).	flagrp170	11-20	premelanosome protein	Mus musculus	144-148
23333935-6	2013	In situ Ad.Flagrp170 therapy provokes systemic activation of CTLs that recognize several antigens naturally expressing in melanoma (e.g., gp100/PMEL and TRP2/DCT).	flagrp170	11-20	tRNA proline 2	Mus musculus	153-157
23333935-6	2013	In situ Ad.Flagrp170 therapy provokes systemic activation of CTLs that recognize several antigens naturally expressing in melanoma (e.g., gp100/PMEL and TRP2/DCT).	flagrp170	11-20	dopachrome tautomerase	Mus musculus	158-161
23333935-8	2013	Antibody neutralization assays show that IL-12 and IFN-gamma are essential for the Flagrp170-elicited antitumor response, which also involves CD8(+) T cells and natural killer cells.	flagrp170	83-92	interferon gamma	Mus musculus	51-60
33468554-8	2021	Additionally, granulocyte macrophage colony-stimulating factor derived from mobilized CD8+ T cells was involved in the therapeutic activity of Flagrp170.	flagrp170	143-152	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	14-62
33468554-10	2021	CONCLUSION: Our results elucidate a novel immune-potentiating activity of Flagrp170 via engaging the innate pattern recognition receptor NLRC4, and support its potential clinical use to reshape cancer immune phenotype for overcoming therapeutic resistance.	flagrp170	74-83	NLR family CARD domain containing 4	Homo sapiens	137-142